Plaquex is used in the treatment of artery disease or atherosclerosis. It is a mixture of essential phospholipids (lecithins or phosphatidylcholines) made from soy beans. It is a new treatment from Europe for atherosclerosis – the deposit of fatty plaques in arteries and other blood vessels. The most important effect of Plaquex is its remarkable ability to reduce plaque deposition in the artery wall. It also lowers blood cholesterol and homocysteine levels.
An important therapeutic application of Plaquex treatment is increasing the heart’s ability to withstand stress. This application is valuable for individuals who have suffered from heart attack or other heart injury. The atherosclerotic plaque that blocks an artery is composed of many constituents, but in general there are two main constituents: cholesterol and calcium. Chelation therapy addresses the calcium. Plaquex addresses the cholesterol component. The cholesterol involved in blocking arteries is the infamous LDL cholesterol. The good HDL cholesterol seems to help reverse the negative effects of the LDL. The chief constituent of good HDL cholesterol is phosphatidylcholine (or plaquex).
Plaquex is not a substitute for EDTA chelation therapy, but is an added treatment for some clients who would benefit from the effects of plaquex. Plaquex cannot be mixed with EDTA chelation so it has to be given as a separate treatment. Unlike chelation with EDTA, Plaquex does not remove toxic heavy metals (ie. Lead, cadmium). Instead it appears to reverse cholesterol transport by creating surrogate HDL cholesterol which aids in the removal of excess LDL cholesterol from the arteries and also appears to lower the level of the highly atherogenic lipoprotein (a) or Lp(a).
In addition, while EDTA chelation can only be used sparingly in the presence of reduced kidney function, Plaquex actually seems to improve or stabilize kidney function in those with pre-existing kidney disease. Plaquex appears to aid in the removal of excess cholesterol from the membranes of cells and along with existing HDL cholesterol, aid in the transport of free cholesterol from deposits in arteries, fat cells, muscle and connective tissue back to the liver, where its excretion is enhanced, It also appears to lower the level of Lp(a) which is a critical factor in the formation of blood clots during heart attacks or stroke.
European Researchers have established that Plaquex has the following therapeutic applications:
Plaquex therapy is administered as an intravenous infusion lasted 90 minutes to 120 minutes. Plaque can be used as a stand alone treatment for lowering cholesterol, improving kidney function and/or improving memory. Plaquex can also be used as part of an integrated treatment program for atherosclerosis along with EDTA chelation and oral supplements.